1. Introduction {#s1}
===============

Platelet activation plays a vital role in the development of cardiovascular disease (CAD). Anti-platelet therapy inhibits platelet aggregation and prevents thrombogenesis and can be used in primary and secondary prevention of CAD. However, according to clinical observations, not all patients are equally sensitive to anti-platelet therapy. Some patients still have different types of ischemic events during therapy, which is defined as anti-platelet therapy resistance.[@b1]

Anti-platelet therapy resistance is detrimental to patients. According to the Heart Outcomes Prevention Evaluation (HOPE) Study, patients with aspirin resistance had a 1.8-fold higher risk of the composite outcome of myocardial infarction (MI), stroke, or cardiovascular death, a two-fold higher risk of myocardial infarction, and a 3.5-fold higher risk of cardiovascular death, when compared with patients who were sensitive to aspirin.[@b2] A multivariate analysis revealed that aspirin resistance is an independent predictor of myonecrosis after percutaneous coronary intervention (PCI) \[odds ratio (OR): 2.9; 95% confidence interval (CI): 1.2--6.9; *P* = 0.015\].[@b3] In another, during follow-up, aspirin resistance was associated with an increased risk of death, myocardial infarction, or cerebrovascular accident (24% *vs.* 10%, hazard ratio: 3.12).[@b4]

Many factors may be involved in the development of anti-platelet therapy resistance. Age, diabetes and acute coronary syndrome are also predictors of anti-platelet therapy resistance.[@b5],[@b6] Thus, there might be an association between risk factors and anti-platelet therapy resistance.

In our study, we established a predictive model for aspirin resistance in elderly Chinese patients, and discussed its calibration and discrimination in identifying high-risk populations.

2. Methods {#s2}
==========

2.1. Ethical approval of the study protocol {#s2a}
-------------------------------------------

Informed consent was obtained from each patient. The study protocol conformed to the Ethical Guidelines of the 1975 Declaration of Helsinki and approved by the Scientific and Ethics Review Board of Chinese PLA General Hospital (Beijing, China).

2.2. Establishment of predictive model {#s2b}
--------------------------------------

We enrolled 1130 patients with chronic CAD and aspirin therapy (\> 75 mg) for \> 2 months from Wanshoulu community, Beijing, China. All the cases had complete clinical and follow-up records. All patients had prior history of cardiovascular disease as defined by previous documented coronary stenosis on cardiac catheterization of ≥ 60%, previous history of MI or stroke, or previous invasive cardiovascular revascularization procedure. All of them received a regular aspirin therapy (100 mg/day) before platelet function assays. Exclusion criteria were; thrombocytopenia (\< 100,000/mm^3^) or thrombocytosis (\> 400,000/mm^3^), anemia (hemoglobin \< 10 g/dL), polycythemia (hematocrit \> 50%), end stage renal disease, acute or chronic liver disease, hematologic diseases, malignancies and history of major surgical procedure within the last month.

Baseline characteristics were collected including age, sex, race, marital status, educational level, smoking, physical activity, body weight, blood pressure, medications and co-morbidities.

Exclusion criteria were as follows: (1) use of heparin, low molecular heparin or other anti-platelet agents within four weeks; (2) surgery within one week before study enrollment; (3) personal or family history of bleeding disorders; (4) platelet count \< 150 × 10^9^/L or \> 450 × 10^9^/L; (5) hemoglobin level \< 80 g/L; (6) history of myeloproliferative diseases; (7) history of drug-induced thrombocytopenia; and (8) history of allergy to aspirin.

2.3. Sample collection {#s2c}
----------------------

Venous blood (15 mL) was collected following overnight fasting for at least 12 h for routine blood testing, blood biochemistry, homocysteine, coagulation function, anti-thrombin III, high sensitivity C-reactive protein (hs-CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), platelet aggregation, and thrombelastography (TEG).

2.4. Light transmittance aggregometry (LTA) {#s2d}
-------------------------------------------

Blood samples were centrifuged at 800 r/min for 5 min to obtain native platelet-rich plasma and further centrifuged at 4000 r/min for 8 min to obtain platelet-poor plasma. The platelet count was assessed using a standard cell counter. Aggregation was performed using arachidonic acid (AA, 0.5 mmol/L) and adenosine diphosphate glucose pyrophospheralase (ADP, 10 µmol/L) with a ChronoLog Aggregometer (Chronolog, Havertown, PA, USA).[@b7]

2.5. TEG {#s2e}
--------

The TEG platelet mapping assay (Haemoscope, Niles, IL, USA) relies on the measurement of platelet function through clot strength. We used AA (1 mmol/L) as a platelet agonist to measure the degree of thromboxane (TX)A~2~-induced platelet aggregation, as previously described.[@b8]

2.6. Definition of laboratory aspirin resistance {#s2f}
------------------------------------------------

LTA, aspirin resistance was defined as both ≥ 20% AA (0.5 mmol/L) and ≥ 70% ADP (10 µmol/L) induced aggregation. Aspirin semi-resistance was defined as either ≥ 20% AA (0.5 mmol/L) or ≥ 70% ADP (10 µmol/L) induced aggregation, but not both of them.[@b9],[@b10] TEG, aspirin resistance was defined as platelet inhibition ≤ 50% induced by AA (1 mmol/L).[@b8]

2.7. Establishment of risk score and stratification {#s2g}
---------------------------------------------------

Risk score were finally established according to the regression coefficient and type of variables in the logistic regression model as follows: (1) definition of weight coefficient. Logistic regression coefficients of each included parameter were converted into an integer risk score by the quotient of the corresponding regression coefficient and the lowest one. The weight coefficient of the parameter with the lowest regression coefficient was defined as 1. (2) Definition of ranked score. When the parameter was binary, if the value = 0, the ranked score = 0; if the value = 1, the ranked score = 1. When the parameter was ordinal, in the lowest grade, ranked score = 0; in the second lowest grade, ranked score = 1, etc. (3) Calculation of risk score. The final score was the product of weight coefficient and ranked score. The predicted risk score for aspirin resistance was estimated by the sum of final scores.

2.8. Evaluation of predictive model {#s2h}
-----------------------------------

A total of 310 cases with chronic stable CAD were recruited from Chinese PLA General Hospital and enrolled in the study. All subjects received a regular aspirin therapy (100 mg/day). Baseline characteristics were collected including age, sex, race, marital status, educational level, smoking, sports, body weight, blood pressure, platelet aggregation, medications and comorbidities.

2.9. Statistical analyses {#s2i}
-------------------------

Categorical variables are presented as frequencies and percentages. For the categorical variables, patient demographics between groups were compared using chi-square tests or, if expected cell frequencies were small, exact tests. Continuous variables are presented as means ± SD. Logistic regression was adopted to establish the predictive model. Variables entered into the model include: age, smoking, body mass index (BMI), blood pressure, coagulation function, serum homocysteine, anti-thrombin III, hs-CRP and NT-proBNP, history of tobacco use, diabetes, hypertension, hyperlipidemia, revascularization, MI, hemoglobin, platelet count, creatinine.

We compared the predicted percentages of aspirin resistance with the actual percentages to evaluate the calibration and discrimination of the predictive model. Calibration was tested by the Hosmer-Lemeshow (HL) test. *P* \> 0.05 was regarded as satisfactory. Discrimination was reflected by the \[area under the receiver operating characteristic (ROC) curve, AUC\]. As AUC approached 1, the better was the discriminative power. All of the statistical analyses were performed by SPSS version 17.0.

3. Results {#s3}
==========

3.1. Patient characteristics {#s3a}
----------------------------

According to the results of both LTA and TEG, patients were grouped into aspirin resistant (AR) (*n* = 119), semi-AR (*n* = 449), and aspirin sensitive (AS) (*n* = 562) groups. Basic characteristics of patients are shown in [Table 1](#jgc-13-05-458-t01){ref-type="table"}. The distributions of quantitative data are shown in [Table 2](#jgc-13-05-458-t02){ref-type="table"}. For the qualitative data (female, smoking, hypertension, diabetes, dyslipidemia, myocardial infarction, cerebral embolism, and peripheral arterial occlusive disease), if there is, value = 1; otherwise, value = 0.

###### Basic characteristics of patients.

  Variables                        AR (*n* = 119)    Semi-AR (*n* = 449)   AS (*n* = 562)    *P* value
  ------------------------------- ----------------- --------------------- ----------------- -----------
  Age, yrs                           79.2 ± 10.1         79.8 ± 9.1          79.3 ± 9.4        0.557
  Smoking                                21                  114                 123           0.002
  Female                                 19                  82                  91            0.018
  BMI, kg/m^2^                      24.98 ± 3.56        24.74 ± 3.40        24.88 ± 3.31       0.664
  Homocysteine, µmol/L              13.49 ± 4.69        14.03 ± 6.09        14.56 ± 7.43       0.475
  NT-proBNP, pg/mL                 155.90 ± 151.80     205.61 ± 255.72     199.34 ± 257.10     0.429
  hs-CRP, mg/dL                      6.55 ± 1.69         5.67 ± 1.31         5.77 ± 2.24       0.001
  Creatinine, µmol/L                85.29 ± 26.26       89.41 ± 39.72       94.65 ± 52.44      0.032
  Fasting serum glucose, mmol/L      6.23 ± 1.57         5.74 ± 1.63         5.69 ± 1.24       0.328
  HbA1c, %                           6.23 ± 1.33         5.89 ± 1.04         5.84 ± 1.07       0.643
  TC, mmol/L                         4.38 ± 0.99         4.40 ± 1.01         4.38 ± 2.12       0.026
  TG, mmol/L                         1.90 ± 1.17         1.70 ± 1.20         1.53 ± 0.80       0.098
  HDL, mmol/L                        1.17 ± 0.32         1.21 ± 0.43         1.28 ± 0.74       0.328
  LDL, mmol/L                        2.50 ± 0.83         2.51 ± 0.78         2.46 ± 0.78       0.061
  Uric acid, µmol/L                334.51 ± 95.92      336.87 ± 92.09      329.79 ± 86.75      0.168
  Platelet, /µL                     182.69 ± 56.3      185.72 ± 51.76      188.45 ± 48.41      0.031
  Hypertension                       32 (26.9%)          162 (36.1%)         277 (49.3%)       0.000
  Diabetes                            50 (42%)           52 (11.6%)           52 (9.3%)        0.009
  PAOD                               21 (17.6%)          56 (12.5%)            45 (8%)         0.337
  Hyperuricemia                       10 (8.4%)           34 (7.6%)            28 (5%)      
   1                                 50 (42.0%)          177 (39.6%)         242 (43.1%)       0.069
   2                                 37 (31.1%)          127 (28.3%)         185 (32.9%)       0.058
   ≥ 3                               32 (26.9%)          145 (32.3%)         135 (24.0%)       0.007
  Left coronary artery involved       9 (7.6%)            24 (5.3%)           18 (3.2%)        0.079
  Medications                                                                               
   Statins                           88 (73.9%)          326 (72.6%)         486 (86.5%)       0.299
   ACEIs/ARBs                        97 (81.5%)          292 (65.0%)         382 (68.0%)       0.068
   β-blockers                        95 (79.8%)          305 (61.1%)         467 (83.1%)       0.871
   Nitrates                          29 (24.4%)          133 (29.6%)         184 (32.7%)       0.462
   PCI                               23 (19.3%)          85 (18.9%)          79 (14.1%)        0.000
   CABG                              19 (16.0%)          37 (32.7%)           51 (9.0%)        0.001

Data are presented as mean ± SD, *n* or *n* (%). ACEIs: angiotensin-converting enzyme inhibitors; AR: aspirin resistant; ARBs: angiotensin receptor blockers; AS: aspirin sensitive; BMI: body mass index; CABG: coronary artery bypass graft; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HbA1c: Hemoglobin A1c; hs-CRP: high-sensitivity C-reactive protein; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; PAOD: peripheral arterial occlusive disease; PCI: percutaneous coronary intervention; TC: total cholesterol; TG: triglyceride.

###### Distributions of quantitative data.

  Variables                                 *n* (%)      Value
  -------------------------------------- -------------- -------
  Age, yrs                                              
   41--50                                  1 (0.08%)       1
   51--60                                  46 (4.07%)      2
   61--70                                 156 (13.8%)      3
   71--80                                 335 (29.6%)      4
   81--90                                 440 (38.9%)      5
   \> 90                                  152 (13.5%)      6
  BMI, kg/m^2^                                          
   \< 20                                   52 (4.6%)       0
   20--25                                 531 (47.0%)      1
   \> 25                                  547 (48.4%)      2
  Homocysteine, µmol/L                                  
   \< 13.9                                638 (56.5%)      0
   ≥ 13.9                                 492 (43.5%)      1
  NT-proBNP, pg/mL                                      
   \< 95                                  494 (43.7%)      0
   95--220                                391 (34.6%)      1
   221--460                               136 (12.0%)      2
   \> 460                                  109 (9.6%)      3
  hs-CRP, mg/dL                                         
   \< 5                                   506 (44.8%)      0
   5--10                                  447 (39.6%)      1
   \> 10                                  177 (15.6%)      2
  Creatinine, µmol/L                                    
   ≤ 110                                  952 (84.2%)      0
   \> 110                                 178 (15.8%)      1
  Fasting serum glucose, mmol/L                         
   \< 6.0                                 767 (67.9%)      0
   6.1--7.0                               212 (18.8%)      1
   \> 7.0                                 151 (13.4%)      2
  HbA1c                                                 
   \< 6.0                                 612 (54.16%)     0
   6.0--7.0                               369 (32.65%)     1
   \> 7.0                                 149 (13.2%)      2
  Uric acid, µmol/L                                     
   \< 390                                 843 (74.6%)      0
   ≥ 390                                  287 (25.4%)      1
  Platelet count, /µL                                   
   \< 100                                  14 (1.2%)       0
   100--200                               751 (66.5%)      1
   201--300                               330 (29.2%)      2
   \> 300                                  35 (3.1%)       3
  Number of involved coronary arteries                  
   1                                      469 (41.5%)      1
   2                                      349 (30.9%)      2
   ≥ 3                                    312 (27.6%)      3

BMI: body mass index; HbA1c: Hemoglobin A1c; hs-CRP: high-sensitivity C-reactive protein; NT-proBNP: N-terminal prohormone of brain natriuretic peptide.

3.2. Establishment of predictive model {#s3b}
--------------------------------------

According to logistic regression analysis, elevated serum creatinine levels, elevated fasting serum glucose levels, dyslipidemia, large number of involved coronary arteries, high BMI, PCI, and smoking were risk factors for aspirin resistance ([Table 3](#jgc-13-05-458-t03){ref-type="table"}).

The percentages of aspirin resistance incidence =

3.3. Risk score and stratification {#s3c}
----------------------------------

We converted all the quantitative data into ordinal data. Risk score was finally established according to regression coefficient and type of variables in the logistic regression model ([Table 4](#jgc-13-05-458-t04){ref-type="table"}). Scores 0--5, 6--10 and \> 10 were classified into low, intermediate and high-risk groups, respectively.

3.4. Evaluation of predictive model {#s3d}
-----------------------------------

Three hundred and ten cases with chronic stable CAD in a hospital in Beijing were collected to evaluate the predictive model. HL test and ROC curve were performed to test calibration and discrimination of the model, respectively. The HL test *P* value was 0.84. AUC was 0.741 (0.712-- 0.771) ([Figure 1](#jgc-13-05-458-g003){ref-type="fig"}). Due to HL test values of *P* \> 0.05 and AUC \> 0.70, our model showed good calibration and discriminative power.

4. Discussion {#s4}
=============

We established a predictive model for aspirin resistance in the present study. According to logistic regression analysis, elevated serum creatinine levels, elevated fasting serum glucose levels, dyslipidemia, large number of involved coronary arteries, high BMI, PCI, and smoking were risk factors for aspirin resistance. The risk score was finally established according to the regression coefficient and type of variables in the logistic regression model.

For example, in a 65-year-old man after PCI, with two branches of involved coronary arteries, BMI: 27 kg/m^2^, normal serum lipid levels, fasting serum glucose: 7.4 mmol/L, and smoking, the steps of stratification were as follows: (1) after PCI = 2, fasting glucose levels 7.4 mmol/L = 1, BMI 27 kg/m^2^ = 2 × 2 = 4, smoking = 3; (2) 2 + 1 + 4 + 3 = 10; and (3) this patient should be classified into the intermediate-risk group.

###### A predictive model for aspirin resistance in the elderly patients with cardiovascular disease (logistic regression analysis).

  Variables                                  B       Wald       *P*       OR        95% CI
  -------------------------------------- --------- -------- ----------- ------- --------------
  Creatinine                               0.107    6.672      0.001     1.316   1.172--1.826
  Fasting serum glucose                    0.207    13.533   \< 0.0001   1.230   1.121--1.402
  Dyslipidemia                             0.211    12.326   \< 0.0001   1.273   1.005--1.664
  Number of involved coronary arteries     0.241    9.688      0.002     1.427   1.205--1.668
  BMI                                      0.253    10.411     0.003     1.594   1.257--1.774
  PCI                                      0.302    7.124    \< 0.0001   1.621   1.296--1.852
  Smoking                                  0.361    5.568      0.018     1.438   1.178--1.609
  Constant                                --0.884   3.680    \< 0.0001          

BMI: body mass index; PCI: percutaneous coronary intervention.

###### Risk score for the predictive model for aspirin resistance.

  Risk factors                            Weight coefficient   Ranked score   Final score
  -------------------------------------- -------------------- -------------- -------------
  Creatinine (\> 110 µmol/L)                      1                 1              1
  Fasting serum glucose \> 7.0                    1                 1              1
  Dyslipidemia                                    1                 1              1
  Number of involved coronary arteries                                       
   2                                              2                 1              2
   ≥ 3                                            2                 2              4
  BMI, kg/m^2^                                                               
   20−25                                          2                 1              2
   \> 25                                          2                 2              4
  After PCI                                       2                 1              2
  Smoking                                         3                 1              3

BMI: body mass index; PCI: percutaneous coronary intervention.

![ROC curve for the evaluation of the predictive model.\
ROC: receiver operating characteristic.](jgc-13-05-458-g001){#jgc-13-05-458-g003}

Many evidence-based studies have shown that clinical risk factors, such as age, diabetes, hypertension, smoking, acute MI, and cardiac insufficiency, can predict thrombotic events in patients with coronary heart disease. Meanwhile, patients with aspirin resistance also have elevated risk for thrombotic events. Case--control studies also show that age, diabetes, and acute coronary syndrome are predictive factors for aspirin resistance.[@b5]--[@b7],[@b11]--[@b13] Among these risk factors, elevated serum creatinine level,[@b14],[@b15] elevated serum glucose level,[@b16],[@b17] dyslipidemia,[@b4],[@b18],[@b19] high BMI,[@b20],[@b21] and smoking,[@b22],[@b23] are consistent with the results from other countries. Large number of involved coronary arteries was not a consistent risk factor.[@b24],[@b25]

Smoking is a major risk factor for cardiovascular diseases. Our study indicates that smoking is also a risk factor for aspirin resistance. In men with coronary heart disease, pre-administration of aspirin failed to prevent smoking-induced platelet aggregation and release of the contents of platelet α granules.[@b26] Multivariate analysis also demonstrated a strong and significant association between smoking and aspirin resistance (relative risk: 11.47, 95% CI: 6.69-- 18.63, *P* \< 0.0001).[@b27] The corresponding mechanism may be involved in the elevated platelet activity by smoking.[@b28]

Dyslipidemia is closely related to chronic inflammation and prothrombotic state. We found that dyslipidemia is a risk factor for aspirin resistance, which is consistent with other studies.[@b11],[@b19],[@b29],[@b30] In a study exploring platelet responsiveness to aspirin in patients with hyperlipidemia, nine of 13 (69%) patients with hyperlipidemia had poor responsiveness to aspirin. Significant correlations were seen between the degree of platelet aggregation and the levels of total cholesterol (*r* = 0.35, *P* = 0.009).[@b29] Recent studies have also implicated that the immunomodulatory dyad CD40/CD40L is also found on endothelial cells, smooth muscle cells, macrophages, T lymphocytes, and platelets in human atheroma. Both membrane-bound and soluble CD40L (sCD40L) interact with CD40 on vascular cells and result in inflammatory and prothrombotic responses.[@b31] *In vitro*, oxidized-LDL promotes expression of CD40 and CD40L in human vascular cells with atheroma.[@b32] *In vivo*, patients with hypercholesterolemia had increased levels of sCD40L, which was also positively correlated with *in vivo* platelet activation, as reflected by 11-dh thromboxane B~2~ and P-selectin.[@b31] Therefore, CD40L--CD40 interaction may play a vital role in the development of aspirin resistance in patients with hyperlipidemia. Whether drugs to treat dyslipidemia are effective for aspirin resistance need further studies.

DiMinno, *et al*.,[@b33] found that dosing schedules for aspirin that may suffice in normal circumstances are not effective in patients with diabetic angiopathy. This phenomenon may be due to a high rate of new platelets in the circulation in these patients. Many later studies have also demonstrated the close relationship between elevated serum glucose and aspirin resistance, which is consistent with our results. A correlation analysis showed that aspirin resistance was positively associated with fasting serum glucose levels (*r* = 0.224, *P* \< 0.001) and hemoglobin A1c (HbA1c) levels (*r* = 0.297, *P* \< 0.0001), which indicates that glycemic control influences aspirin resistance in patients with diabetes.[@b21] In patients with diabetes, there is a significant correlation between TXB~2~ production and fasting serum glucose and HbA1c. This association suggests that hyperglycemia is a determinant of the reduced sensitivity to aspirin in diabetes.[@b34] According to our study, high BMI also increased the risk of aspirin resistance. The positive correlation between BMI and aspirin resistance (*r* = 0.190, *P* \< 0.01) has also been shown in another study.[@b21] One possibility is attributed to the increase in leptin in patients with obesity, which induces hypercoagulability. Another reason is the low concentration of drug distribution. Many later studies have also demonstrated the close relationship between elevated serum glucose and aspirin resistance, which is consistent with our results.

We also examined an independent group of people involving 310 cases with chronic, stable coronary heart disease in a Beijing hospital to evaluate our predictive model. The model showed good calibration and discriminative power in which the HL test *P* \> 0.05 and AUC \> 0.70. Ac-cording to the inclusion and exclusion criteria, this predictive model was applicable to cases with chronic, stable coronary heart disease and receiving oral aspirin medication.
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